Definium Therapeutics rises after anxiety disorder drug meets late-stage trial goal
12/08/2026 12:42
BUZZ-Definium Therapeutics rises after anxiety disorder drug meets late-stage trial goal ** Shares of biotech firm Definium Therapeutics DFTX.O rise 22.2% to $50.01 premarket
** Co says its LSD-based experimental pill significantly reduced anxiety symptoms in adults with generalized anxiety disorder, or GAD in a late-stage study, meeting the trial's main goal
** Patients on the drug had an 11.6-point drop on a standard anxiety rating scale at week 12, compared with a 6.2-point drop for those on a placebo - DFTX
** Most side effects were mild to moderate and temporary, occurring mainly on the day of dosing, with no increase in suicidal thoughts - DFTX
** As of last close, DFTX up 205.5% YTD
(Reporting by Kunal Das in Bengaluru)